Sharemaestro company-news research for Surgery Partners Inc (SGRY), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest SGRY news and sentiment
Surgery Partners Inc
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
25 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone61/100
→
Published 30-day score53/100
Latest source headline
Surgery Partners (SGRY) Faces Softer Volumes With Fair Value Still Higher
finance.yahoo.com · 10 Oct 2026 07:14
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
25 current stories are mapped specifically to SGRY.
The score uses 15 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.398.
Confidence is 29/100, below the threshold for a firm score.
53/100
News scoreEarly balanced news score
29/100
Confidencethin evidence
95%/100
Company news25 company stories
91/100
Story agreement9/100 difference
News history
Daily score and story count over 30 days
11 Sep26 Sep10 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence8
0.398 after freshness weightingSource breadth100
15 independent publishersCompany relevance95
share tied directly to this companyFreshness50
recency-weighted evidenceAgreement91
how closely stories agreePublisher mix84
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks25 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
17 Apr14 Jul09 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
09 Oct 202652USD 13.89+4.3%
02 Oct 202652USD 13.32-7.5%
25 Sep 202651USD 14.4+8.7%
18 Sep 202649USD 13.25-7.9%
11 Sep 202652USD 14.38+0.8%
04 Sep 202654USD 14.26+4.2%
28 Aug 202656USD 13.69-5.7%
21 Aug 202659USD 14.52-3.4%
Provisional evidence
News subjects
What is shaping the score
Market update5610 stories · 40%
Analyst action626 stories · 24%
Balance sheet484 stories · 16%
Earnings443 stories · 12%
Guidance502 stories · 8%
Source mix
Where the evidence comes from
Simply Wall Street513 stories · 12%
simplywall.st503 stories · 12%
MT Newswires282 stories · 8%
AD HOC NEWS642 stories · 8%
GuruFocus632 stories · 8%
Stock Titan572 stories · 8%
finance.yahoo.com512 stories · 8%
Recurring subjects
Subjects appearing most often
Earnings13Life Sciences12Financial Markets8Mergers And Acquisitions5Healthcare3Finance3Share Price2Debt2Balance Sheet2Valuation1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
01 Jul50 neutral10 Oct 19:01
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 10 Oct 19:01 | 53 | +1 | 30/100 (+2) | 25 (+1) | Provisional |
| 09 Oct 23:59 | 52 | -1 | 28/100 (-3) | 24 (+1) | Provisional |
| 08 Oct 23:59 | 53 | +1 | 31/100 (+1) | 23 (+2) | Provisional |
| 07 Oct 23:59 | 52 | +1 | 30/100 (+6) | 21 (+2) | Provisional |
| 06 Oct 23:59 | 51 | -1 | 24/100 (-6) | 19 (0) | Provisional |
| 02 Oct 23:59 | 52 | +0 | 30/100 (-5) | 19 (0) | Provisional |
| 30 Sep 23:59 | 52 | +1 | 35/100 (+12) | 19 (+3) | Provisional |
| 29 Sep 23:59 | 51 | +0 | 23/100 (-2) | 16 (+1) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 25 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Analyst action4 stories
0.0%58.7%
Market update4 stories
0.7%20.7%
Balance sheet2 stories
7.7%7.2%
Earnings2 stories
2.4%2.5%
Each side uses the same scale: 0–58.7% of the retained directional evidence.
Where the influence comes from
30.8%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
59/100 tone
Recent commentary around Surgery Partners (SGRY) has focused on softer unit sales over the past two years, a projected decline in sales over the next 12 months, and a relatively high forward P/E multiple. At a share price of US$13.89, Surgery Partners has seen short term momentum pick up,…
19.3% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Recent commentary around Surgery Partners (SGRY) has focused on softer unit sales over the past two years, a projected decline in sales over the next 12 months, and a relatively high forward P/E multiple. At a share price of US$13.89, Surgery Partners has seen short term momentum pick up, with a 1 day share price return of 1.83% and a 7 day share price return of 4.28%. However, the 90 day share price return is down 15.30% and the 1 year total shareholder return has fallen 29.64%, pointing to fading longer term sentiment as investors reassess slower unit volumes, leverage concerns and a richer
- Published
- 10 Oct 2026 07:14
- News subject
- Market update
- Why this score
- Strategic partnership
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 48/100
- 30-day weight
- 19.3% of directional evidence · 0.5d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Balance SheetDebtHealthcareMarginsShare PriceShareholder
—Unscored
Balance sheetNot used in direction
Is Surgery Partners (SGRY) Cheap After a 65% Five Year Fall?
Surgery Partners has seen its share price fall sharply over recent years, which puts the spotlight squarely on whether the current valuation can be explained by the cash the business is expected to generate. With the stock recently closing at US$13.64, the key issue is how that market pri…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Surgery Partners has seen its share price fall sharply over recent years, which puts the spotlight squarely on whether the current valuation can be explained by the cash the business is expected to generate. With the stock recently closing at US$13.64, the key issue is how that market price lines up against the cash flow profile implied by a Discounted Cash Flow (DCF) view. Over the past 5 years, Surgery Partners has delivered a share price decline of 65.2%, which raises the question of what the market thinks about its long term cash generation today. The business model relies on converting pr
- Published
- 09 Oct 2026 21:13
- News subject
- Balance sheet
- Why this score
- Negative market reaction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 0.9d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Cash FlowDiscounted Cash FlowFree Cash FlowHealthcareIntrinsic ValueShare Price
—Unscored
Market updateNot used in direction
McDermott Will & Schulte advises Surgery Partners on sale of ownership interests in Idaho Falls facilities
McDermott Will & Schulte advised Surgery Partners (NASDAQ: SGRY) on the sale of its majority ownership interest in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health. The transaction, valued at approximately $1.15 billion, with Surgery Partners receiving abo…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
McDermott Will & Schulte advised Surgery Partners (NASDAQ: SGRY) on the sale of its majority ownership interest in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health. The transaction, valued at approximately $1.15 billion, with Surgery Partners receiving about $797 million in gross proceeds, marks a significant step in Surgery Partners' portfolio optimization strategy. This complex deal involved multiple stakeholders and significant antitrust and healthcare regulatory considerations.
- Published
- 08 Oct 2026 03:35
- News subject
- Market update
- Why this score
- Strategic partnership
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 2.6d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Life SciencesMergers And Acquisitions
69/100 tone
Surgery Partners stock gained 2.24% on October 7, 2026, after Cantor Fitzgerald reiterated an Overweight rating and a USD 18.00 price target. Despite revenue beating forecasts in Q2 2026, the company reported an adjusted loss, leading to a mixed operating picture. Analysts maintain a "Mod…
30.8% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Surgery Partners stock gained 2.24% on October 7, 2026, after Cantor Fitzgerald reiterated an Overweight rating and a USD 18.00 price target. Despite revenue beating forecasts in Q2 2026, the company reported an adjusted loss, leading to a mixed operating picture. Analysts maintain a "Moderate Buy" consensus with an average price target of USD 19.00, significantly above its current market price.
- Published
- 08 Oct 2026 03:32
- News subject
- Analyst action
- Why this score
- Strategic partnership
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 57/100
- 30-day weight
- 30.8% of directional evidence · 2.6d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
61/100 tone
Cantor Fitzgerald has reiterated its Overweight rating on Surgery Partners (NASDAQ: SGRY) with an $18.00 price target, suggesting a 35% upside despite a recent 35% stock decline. Analysts project profitability for SGRY this year, with expected earnings of $0.32 per share. The company is n…
23.6% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Cantor Fitzgerald has reiterated its Overweight rating on Surgery Partners (NASDAQ: SGRY) with an $18.00 price target, suggesting a 35% upside despite a recent 35% stock decline. Analysts project profitability for SGRY this year, with expected earnings of $0.32 per share. The company is not experiencing staffing shortages, and recent data indicates stable ambulatory surgery center openings and a decrease in average bonus payments.
- Published
- 07 Oct 2026 02:58
- News subject
- Analyst action
- Why this score
- Strategic partnership
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 45/100
- 30-day weight
- 23.6% of directional evidence · 3.7d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinanceFinancial MarketsLife Sciences
—Unscored
Analyst actionNot used in direction
RBC reiterates target for Surgery Partners stock at USD 19.00
RBC Capital has reiterated its Outperform rating for Surgery Partners (SGRY) stock, setting a price target of USD 19.00. This follows Surgery Partners' recent sale of interests in two Idaho hospitals, generating USD 587 million in net cash proceeds primarily intended for debt reduction. T…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
RBC Capital has reiterated its Outperform rating for Surgery Partners (SGRY) stock, setting a price target of USD 19.00. This follows Surgery Partners' recent sale of interests in two Idaho hospitals, generating USD 587 million in net cash proceeds primarily intended for debt reduction. The divestiture led to a revised 2026 revenue guidance of USD 3.08-3.18 billion and adjusted EBITDA of at least USD 489 million, reflecting a more focused operating portfolio despite a lower consolidated scale.
- Published
- 07 Oct 2026 01:24
- News subject
- Analyst action
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 3.7d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Analyst actionNot used in direction
Why Surgery Partners (SGRY) Is Back In The Spotlight
Surgery Partners (SGRY) has seen renewed attention after its share price reached $13.41, despite weak long-term returns. The company is currently trading below analyst targets and intrinsic value, with a fair value estimated at $17.95, suggesting it is 25% undervalued. However, higher int…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Surgery Partners (SGRY) has seen renewed attention after its share price reached $13.41, despite weak long-term returns. The company is currently trading below analyst targets and intrinsic value, with a fair value estimated at $17.95, suggesting it is 25% undervalued. However, higher interest costs and slower acquisitions could challenge this undervalued narrative, urging investors to examine the underlying financial data and risks closely.
- Published
- 06 Oct 2026 22:11
- News subject
- Analyst action
- Why this score
- Positive valuation view
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 3.9d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Surgery Partners, Inc. (SGRY) Stock Price, News, Quote & History
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 02 Oct 2026 20:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 8.0d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
61/100 tone
Surgery Partners Inc (SGRY) shares recently dropped 3.8% and are considered undervalued by the GF Value™ estimate, suggesting a 43.5% upside. However, the company's current unprofitability, negative cash flow, and significant net insider selling ($1.1M) raise concerns and caution investor…
1.4% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Surgery Partners Inc (SGRY) shares recently dropped 3.8% and are considered undervalued by the GF Value™ estimate, suggesting a 43.5% upside. However, the company's current unprofitability, negative cash flow, and significant net insider selling ($1.1M) raise concerns and caution investors. SGRY holds an "Above Average" GF Score™ of 64/100, with strong points in valuation and momentum, but weaknesses in financial strength and profitability.
- Published
- 30 Sep 2026 23:27
- News subject
- Market update
- Why this score
- Positive valuation view
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 36/100
- 30-day weight
- 1.4% of directional evidence · 9.8d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
43/100 tone
RBC analysts view Surgery Partners' sale of its Idaho Falls facilities as a move that strengthens the company's core strategy. The article suggests this sale is a significant step for Surgery Partners. Full details are behind a premium paywall.
0.7% of directional evidence
Low story strength
Scoring detailsDirect company coverage
RBC analysts view Surgery Partners' sale of its Idaho Falls facilities as a move that strengthens the company's core strategy. The article suggests this sale is a significant step for Surgery Partners. Full details are behind a premium paywall.
- Published
- 30 Sep 2026 15:10
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 30/100
- 30-day weight
- 0.7% of directional evidence · 10.2d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Mergers And Acquisitions
63/100 tone
RBC Capital has reiterated its Outperform rating on Surgery Partners (SGRY) with a price target of $19.00, representing a 31.9% upside from its previous close. This positive outlook is based on the company's strategic portfolio optimization through the divestiture of Idaho Falls facilitie…
4.2% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
RBC Capital has reiterated its Outperform rating on Surgery Partners (SGRY) with a price target of $19.00, representing a 31.9% upside from its previous close. This positive outlook is based on the company's strategic portfolio optimization through the divestiture of Idaho Falls facilities, enhancing its focus as an outpatient surgical platform, and its targeted growth strategy involving M&A and expansion into high-acuity procedures.
- Published
- 30 Sep 2026 14:04
- News subject
- Analyst action
- Why this score
- Strategic partnership
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 39/100
- 30-day weight
- 4.2% of directional evidence · 10.2d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
—Unscored
GuidanceNot used in direction
Surgery Partners (NasdaqGS:SGRY) Stock Forecast & Analyst Predictions
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 29 Sep 2026 07:00
- News subject
- Guidance
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 11.5d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
GuidanceNot used in direction
Surgery Partners (SGRY) Updates 2026 Guidance On Idaho Falls Change As Valuation Stays In Focus
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 27 Sep 2026 06:46
- News subject
- Guidance
- Why this score
- Strategic partnership
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 13.5d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Idaho Falls Sale Might Change The Case For Investing In Surgery Partners Stock (SGRY)
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 25 Sep 2026 14:30
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 15.2d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know
Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know What Happened? A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid Services mov…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know What Happened? A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid Services moved to cancel Affordable Care Act coverage for roughly 760,000 people and claw back billions in subsidies. The Health Care Select Sector SPDR Fund slipped 0.91% in regular trading, according to exchange data. CMS canceled approximately 315,000 enrollments covering over 760,000 individuals following an investiga
- Published
- 23 Sep 2026 21:30
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.9d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial ResultsHealthcareRegulationTech
76/100 tone
Surgery Partners SGRY shares ended the last trading session 15.7% higher at $15.8. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2.1% loss over the past four weeks. Surgery Partners scored a st…
<0.1% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Surgery Partners SGRY shares ended the last trading session 15.7% higher at $15.8. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2.1% loss over the past four weeks. Surgery Partners scored a strong price increase, driven by investors' optimism following the announcement that it has completed the sale of its ownership interests in its Idaho Falls facilities to Intermountain Health. Under the terms of the Securities Purchase Agreements, Surgery Partners received $797 million in gross proceeds and $587
- Published
- 23 Sep 2026 10:26
- News subject
- Market update
- Why this score
- Large positive market reaction
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 46/100
- 30-day weight
- <0.1% of directional evidence · 17.4d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsEarnings EstimateMedical ServicesPrice MovementsQuarterly EarningsRevenue Growth
—Unscored
EarningsNot used in direction
Surgery Partners (SGRY): Buy, Sell, or Hold Post Q2 Earnings?
Surgery Partners (SGRY): Buy, Sell, or Hold Post Q2 Earnings? Surgery Partners's 30.8% return over the past six months has outpaced the S&P 500 by 12.8%, and its stock price has climbed to $15.67 per share. This was partly thanks to its solid quarterly results, and the run-up might have i…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Surgery Partners (SGRY): Buy, Sell, or Hold Post Q2 Earnings? Surgery Partners's 30.8% return over the past six months has outpaced the S&P 500 by 12.8%, and its stock price has climbed to $15.67 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move. Is now the time to buy Surgery Partners, or should you be careful about including it in your portfolio? See what our analysts have to say in our full research report, it's free. Why Is Surgery Partners Not Exciting? We're glad investors have benefited from the price incr
- Published
- 23 Sep 2026 04:06
- News subject
- Earnings
- Why this score
- Positive market reaction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 17.6d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Balance SheetDebtEarningsQuarterly ResultsValuation
59/100 tone
Surgery Partners (SGRY) revised its 2026 revenue outlook to $3.08 billion to $3.18 billion, attributing the change to the removal of Idaho Falls Facilities' contribution. This update follows significant share price declines, with the stock down 7.86% in the past week and 13.17% year-to-da…
2.5% of directional evidence
Low story strength
Scoring detailsDirect company coverage
Surgery Partners (SGRY) revised its 2026 revenue outlook to $3.08 billion to $3.18 billion, attributing the change to the removal of Idaho Falls Facilities' contribution. This update follows significant share price declines, with the stock down 7.86% in the past week and 13.17% year-to-date, raising questions about its valuation. Despite the pressure, the company is seen as undervalued by some analysts who highlight its strong position in the outpatient surgical procedures market.
- Published
- 20 Sep 2026 20:21
- News subject
- Earnings
- Why this score
- Strategic partnership
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 33/100
- 30-day weight
- 2.5% of directional evidence · 19.9d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Can Intuitive Surgical Make Up For A Lower Price Per Surgery?
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 18 Sep 2026 12:33
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 22.3d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
42/100 tone
Surgery Partners Inc. (NASDAQ: SGRY) has sold its Idaho Falls facilities, including Mountain View Hospital and Idaho Falls Community Hospital, to Intermountain Health for $797 million in gross proceeds. This strategic move aims to streamline Surgery Partners' business portfolio, reduce de…
7.7% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Surgery Partners Inc. (NASDAQ: SGRY) has sold its Idaho Falls facilities, including Mountain View Hospital and Idaho Falls Community Hospital, to Intermountain Health for $797 million in gross proceeds. This strategic move aims to streamline Surgery Partners' business portfolio, reduce debt, and improve leverage. The company has updated its full-year 2026 guidance to reflect the divestment, projecting lower revenue and adjusted EBITDA excluding the sold facilities.
- Published
- 18 Sep 2026 08:05
- News subject
- Balance sheet
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 37/100
- 30-day weight
- 7.7% of directional evidence · 22.5d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinanceLife SciencesMergers And Acquisitions
—Unscored
Balance sheetNot used in direction
Surgery Partners gets $587M cash as Intermountain buys Idaho hospitals
Surgery Partners (SGRY) has completed the sale of its Idaho Falls facilities, including Mountain View Hospital and Idaho Falls Community Hospital, to Intermountain Health for $797 million in gross proceeds and $587 million in net cash. The company plans to use the proceeds primarily to pa…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Surgery Partners (SGRY) has completed the sale of its Idaho Falls facilities, including Mountain View Hospital and Idaho Falls Community Hospital, to Intermountain Health for $797 million in gross proceeds and $587 million in net cash. The company plans to use the proceeds primarily to pay down debt, expecting a 30 basis point improvement in balance sheet leverage. This transaction streamlines Surgery Partners' business, leading to updated 2026 guidance with reduced revenue and adjusted EBITDA projections, while physician ownership of Mountain View Hospital remains unchanged.
- Published
- 17 Sep 2026 20:21
- News subject
- Balance sheet
- Why this score
- Guidance cut, Balance sheet strengthened, Strategic partnership
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 22.9d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsLife SciencesMergers And Acquisitions
24/100 tone
2.4% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
- Published
- 17 Sep 2026 14:03
- News subject
- Earnings
- Why this score
- Guidance cut
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 52/100
- 30-day weight
- 2.4% of directional evidence · 23.2d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
66/100 tone
Surgery Partners, Inc. (SGRY) has completed the sale of its Idaho Falls hospital interests, including Mountain View Hospital and Idaho Falls Community Hospital, to Intermountain Health for approximately $797 million gross proceeds and $587 million net cash. The company plans to use these …
7.2% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Surgery Partners, Inc. (SGRY) has completed the sale of its Idaho Falls hospital interests, including Mountain View Hospital and Idaho Falls Community Hospital, to Intermountain Health for approximately $797 million gross proceeds and $587 million net cash. The company plans to use these proceeds primarily to reduce debt, which is expected to improve balance sheet leverage by 30 basis points. This divestment aims to streamline Surgery Partners' business, focusing on its core short-stay surgical provider model and enhancing adjusted earnings growth and free cash flow conversion.
- Published
- 15 Sep 2026 22:28
- News subject
- Balance sheet
- Why this score
- Strategic partnership, Operating growth, Balance sheet strengthened
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 46/100
- 30-day weight
- 7.2% of directional evidence · 24.9d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinanceLife SciencesMergers And Acquisitions
77/100 tone
JP Morgan has maintained a Neutral rating on Surgery Partners (SGRY) but raised its price target to $15.00 from $14.00, reflecting cautious optimism despite the stock being 42.1% undervalued by GF Value™. The company has a GF Score™ of 61/100, with concerns regarding financial strength an…
0.2% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
JP Morgan has maintained a Neutral rating on Surgery Partners (SGRY) but raised its price target to $15.00 from $14.00, reflecting cautious optimism despite the stock being 42.1% undervalued by GF Value™. The company has a GF Score™ of 61/100, with concerns regarding financial strength and profitability, but shows positive momentum and recent insider buying. Investors are advised to proceed with caution due to the company's unprofitability and cash-flow challenges.
- Published
- 15 Sep 2026 00:01
- News subject
- Analyst action
- Why this score
- Analyst upgrade, Positive valuation view, Strategic partnership
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 52/100
- 30-day weight
- 0.2% of directional evidence · 25.8d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Surgery Partners (SGRY) Could Be 20% Undervalued Following Its Recent Bounce
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 12 Sep 2026 13:33
- News subject
- Market update
- Why this score
- Positive valuation view
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 28.2d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
Earlier company news
SGRY news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 99 older SGRY headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to SGRY, but the headline and available text are not mainly about Surgery Partners Inc. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of SGRY sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.